Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Income (2022 - 2025)

Axsome Therapeutics' Net Income history spans 4 years, with the latest figure at -$28.6 million for Q4 2025.

  • For Q4 2025, Net Income rose 61.78% year-over-year to -$28.6 million; the TTM value through Dec 2025 reached -$183.2 million, up 36.21%, while the annual FY2025 figure was -$183.2 million, 36.21% up from the prior year.
  • Net Income for Q4 2025 was -$28.6 million at Axsome Therapeutics, up from -$47.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$11.2 million in Q1 2023 and bottomed at -$98.7 million in Q4 2023.
  • The 4-year median for Net Income is -$60.3 million (2022), against an average of -$56.0 million.
  • The largest annual shift saw Net Income soared 71.64% in 2023 before it plummeted 508.27% in 2024.
  • A 4-year view of Net Income shows it stood at -$61.2 million in 2022, then crashed by 61.12% to -$98.7 million in 2023, then grew by 24.08% to -$74.9 million in 2024, then skyrocketed by 61.78% to -$28.6 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Net Income are -$28.6 million (Q4 2025), -$47.2 million (Q3 2025), and -$48.0 million (Q2 2025).